Clinical Features and Management of Eosinophilic Asthma

Asthma is a complex chronic airway disease with several distinct phenotypes with different immunopathological pathways, clinical presentation, physiology, cormobidities, biomarker of allergic inflammation, and response to treatment [1-4]. There are several distinct proposed asthma phenotypes, such as childhood-ons et al. lergic asthma, adult-onset eosinophilic asthma,neutrophilic asthma, exercise-induced asthma (EIA), obesity-related asthma, and aspirin-exacerbated respiratory disease (AERD) [5-7]. Severe asthma represents about 5-10% of patients with asthma, and about 50% of these patients present with eosinophilic asthma [8-10]. The guidelines on the definition, evaluation and treatment of severe refractory asthma including eosinophilic asthma are given in detail by thethe American Thoracic Society (ATS) [11], and the European Respiratory Society (ERS) [12]. Severe asthma is defined by the joint ERS/ATS according to the following criteria [12]: